Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Viridian Therapeutics, Inc. (NASDAQ: VRDN)
VRDN Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
356.30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
107.70%
VRDN Stock Analysis
VRDN
PE Ratio:
VRDN
PEG Ratio:
Not Available
VRDN
Forward EPS Growth (12 month):
0.00%
VRDN
PS Ratio:
20.7
VRDN
PSG Ratio:
0.1
VRDN
Forward Revenue Growth (12 month):
400.00%
VRDN Articles
No data was found